| Compound Information | SONAR Target prediction |
| Name: | Vancomycin hydrochloride |
| Unique Identifier: | Prest816 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | C66Cl3H76N9O24 |
| Molecular Weight: | 1414.15 g/mol |
| X log p: | 21.566 (online calculus) |
| Lipinksi Failures | 3 |
| TPSA | 191.94 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 33 |
| Rotatable Bond Count: | 14 |
| Canonical Smiles: | Cl.CNC(CC(C)C)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(O)C5NC(=O)C(NC (=O)C4NC(=O)C(CC(N)=O)NC1=O)c1ccc(O)c(c1)c1c(O)cc(O)cc1C(NC5=O)C(O)=O) c3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1)c(Cl)c2 |
| Generic_name: | Vancomycin |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA451850 |
| Kegg_compound_id: | C06689 |
| Drugbank_id: | APRD01287 |
| Logp: | -0.47 |
| Cas_registry_number: | 1404-90-6 |
| Drug_category: | Anti-Bacterial Agents; Glycopeptide antibacterials; ATC:A07AA09; ATC:J01XA01 |
| Indication: | For the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. |
| Pharmacology: | Vancomycin is a branched tricyclic glycosylated nonribosomal peptide produced by the fermentation of the Actinobacteria species Amycolatopsis orientalis (formerly Nocardia orientalis). It is often reserved as the "drug of last resort", used only after treatment with other antibiotics had failed. Vancomycin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: Listeria monocytogenes, Streptococcus pyogenes, Streptococcus pneumoniae (including penicillin-resistant strains), Streptococcus agalactiae, Actinomyces species, and Lactobacillus species. The combination of vancomycin and an aminoglycoside acts synergistically in vitro against many strains of Staphylococcus aureus, Streptococcus bovis, enterococci, and the viridans group streptococci. |
| Mechanism_of_action: | The bactericidal action of vancomycin results primarily from inhibition of cell-wall biosynthesis. Specifically, vancomycin prevents incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits from being incorporated into the peptidoglycan matrix; which forms the major structural component of Gram-positive cell walls. The large hydrophilic molecule is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Normally this is a five-point interaction. This binding of vancomycin to the D-Ala-D-Ala prevents the incorporation of the NAM/NAG-peptide subunits into the peptidoglycan matrix. In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis. There is no cross-resistance between vancomycin and other antibiotics. Vancomycin is not active in vitro against gram-negative bacilli, mycobacteria, or fungi. |
| Organisms_affected: | Enteric bacteria and other eubacteria |
| Found: 3 nonactive as graph: single | with analogs | 1 2 3 Next >> |
| Species: | 9606 |
| Condition: | TMPPre001 |
| Replicates: | 2 |
| Raw OD Value: r im | 2043.0000±0 |
| Normalized OD Score: sc h | 1.0271±0 |
| Z-Score: | 0.6096±0 |
| p-Value: | 0.542114 |
| Z-Factor: | -5.02836 |
| Fitness Defect: | 0.6123 |
| Bioactivity Statement: | Nonactive |
| ps |
| DBLink | Rows returned: 27 | 1 2 3 4 5 Next >> |
| 5651 | n/a |
| 14969 | n/a |
| 14970 | n/a |
| 14971 | n/a |
| 124741 | n/a |
| 198480 | -1 |
| internal high similarity DBLink | Rows returned: 0 |
| nonactive | Cluster 1 | Additional Members: 50 | Rows returned: 45 | << Back 1 2 3 4 5 6 7 8 |
| LAT006D07 | 0 |
| LAT006C07 | 0 |
| LAT006D06 | 0 |
Service provided by the
Mike Tyers Laboratory